Background/Aims: This post-marketing observational study assessed the long-term safety of lanthanum carbonate (LaC) in US patients with end-stage renal disease (NCT00567723). Methods: Patients (≥18 years old) undergoing dialysis, who had Medicare as their primary healthcare payer, and records in the United States Renal Data System were followed-up for 5 years. Patients who had received LaC for at least 12 consecutive weeks formed the exposed cohort. During the same time period, patients who had undergone dialysis for at least 12 consecutive weeks and had been treated with any other phosphate binder formed the primary comparator cohort. A historical cohort was also evaluated. Primary outcomes were all-cause mortality, and time to and incidence of first bonefracture event requiring hospitalization. Secondary outcomes were time to first occurrence of and incidence of specific gastrointestinal (GI) disease, liver disease, malignancy, and major infectious episode requiring hospitalization. Results: 2,026 and 8,094 patients were included in the exposed and primary comparator cohorts, respectively. A Cox proportional hazards model showed that patients receiving LaC were not at increased risk of all-cause mortality (adjusted hazard ratio 0.94; 95% CI 0.88-1.01; p = 0.078), bone fractures (0.86; p = 0.130), specific GI disease (0.86; p = 0.015), liver disease (0.88; p = 0.236), malignancy (0.85;; p = 0.496), or major infectious episodes (0.87; 0.80-0.94; p < 0.001) requiring hospitalization compared with primary comparator patients. Conclusions: LaC was not associated with increased risk of mortality, bone fractures, or any secondary outcome.
Introduction
Hyperphosphatemia is one of the main clinical manifestations of end-stage renal disease (ESRD) caused by the progressive deterioration of kidney function [1, 2] . Hyperphosphatemia is associated with an increased risk of measures were obtained from the United States Renal Data System (USRDS) for all cohorts. The comparator cohorts were identified from the USRDS. The study was initiated in April 2006, study sites were closed in 2012, and data continued to be collected via the USRDS until completion in June 2016.
The exposed cohort was identified from 158 clinical sites in the USA. These patients had received LaC either through participating in another ongoing or completed clinical trial, or by being prescribed LaC as part of their normal clinical care. Patients did not receive LaC specifically for the purposes of this study. To be included in this study, post-baseline data in the USRDS were required. All patients in the exposed group were identified from the clinical sites and provided written informed consent before participating in the current study. After this, relevant data were obtained through the USRDS. This study was therefore registered as a clinical trial, despite the fact that baseline comorbidity data and outcome data for comparisons represented epidemiologic data extractions from the USRDS. Inclusion criteria for the patients in the exposed cohort were: aged ≥18 years; diagnosed with ESRD; undergoing dialysis; had Medicare as their primary healthcare payer (to allow identification in the USRDS); had received LaC for a minimum of 12 consecutive weeks (but not necessarily still receiving LaC at screening); and had at least 1 post-screening record in the USRDS (e.g., transplant, dialysis, or death). Patients in this cohort could switch from LaC to another therapy during the follow-up period or could cease LaC therapy; however, these data were not captured from the USRDS.
The comparator groups were selected from the USRDS by frequency matching to the exposed cohort USRDS record. Patients in the primary comparator cohort had been diagnosed with ESRD, were ≥18 years old, had undergone dialysis for a minimum of 12 consecutive weeks, and had been treated for hyperphosphatemia with any phosphate binder other than LaC during the time of this study (these patients had not necessarily had 12 weeks of phosphate-binder therapy). This cohort was identified retrospectively from patients who were not treated with LaC for the length of the observation period and frequency-matched to the exposed cohort by age at screening (5-year intervals), sex, and the year of starting dialysis (±1 year). Observation for both the exposed and primary comparator was obtained from the screening date of the exposed patient to transplant, death, the screening date plus 5 years, or withdrawal of consent (exposed cohort patients). Individuals in the historical comparator cohort were matched using the same criteria as those in the primary comparator cohort. Duration of dialysis for the historical comparator cohort was calculated from dialysis start date to January 1, 2000. Patients in the historical comparator cohort had to have data in the USRDS on January 1, 2000 (i.e., 5 years before LaC became available in the USA to allow for the observation period). Observation for the historical comparator cohort was from January 1, 2000 to transplant, death, or the screening date (January 1, 2000) plus 5 years. For each exposed patient, up to 4 primary and 4 historical matched comparators were selected from the USRDS. If more than 4 individuals had matching attributes with an exposed patient, a randomization schedule was utilized to select the 4 matched comparator patients. The matching was performed so that there was no overlap between the cohorts.
Data were obtained from the USRDS every 6 months during the observation period. This study was conducted in accordance 
Study Outcome Measures
The primary outcomes were time to and incidence of all-cause mortality, and time to and incidence of first bone-fracture event requiring hospitalization over a 5-year period. The secondary outcomes were time to first event and incidence of specific GI disease requiring hospitalization, liver disease requiring hospitalization, malignancy requiring hospitalization, or major infectious episode requiring hospitalization. The International Classification of Diseases, Ninth Revision diagnosis codes were used for primary and secondary outcomes (online suppl. Table S1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000492603), since these codes were in use in the USRDS at the time that the study was conducted.
Data Source
The USRDS is a national database collecting information about chronic kidney disease and ESRD in the USA. All patients with ESRD are included in the USRDS, irrespective of their insurance coverage or age; however, claims analyses (which include analyses of hospitalization data) are restricted to Medicare patients [25] . In the USA, Medicare healthcare insurance covers people of all ages who have ESRD. When a patient enrolls in Medicare based on ESRD and is receiving dialysis, Medicare coverage usually starts on the first day of the fourth month of dialysis. This waiting period will start even if the patient has not signed up for Medicare. Hence, in the USA, essentially all chronic dialysis patients have comprehensive Medicare medical insurance on or before 3 months of dialysis treatment. USRDS data on hospitalizations, diagnoses, renal transplants, and deaths, as well as potential confounders (e.g., comorbidities) for the exposed cohort, were extracted and combined with phosphate-binder exposure data. The records were then searched to identify study outcomes that occurred after treatment with LaC in patients in the exposed cohort. For patients in the 2 comparator cohorts, the follow-up data from the USRDS included records generated from the screening date to the withdrawal/ completion date.
Statistical Analyses
All statistical analyses were performed in SAS ® version 9.4 (SAS Institute, Cary, NC, USA). A Cox proportional hazards (CPH) model was used to compare time to first event for primary and secondary outcomes in the exposed cohort versus the primary comparator cohort, and in the exposed cohort versus the historical comparator cohort. The hazard ratio (HR) and 95% CI are reported. The model was adjusted for patient baseline characteristics. The covariate terms used were: age category (18-45, 46-65, 66-75, and > 75 years); sex; sex by age category interaction; year of starting dialysis (exposed versus primary comparator); duration of dialysis at screening (exposed versus historical comparator); study cohort; region (online suppl. Table S2) ; race (white, black, Asian, other); tobacco use (yes/no/unknown); diabetes mellitus (yes/no/unknown); previous event of interest (yes/no; included for all analyses except for all-cause mortality); type of dialysis (hemodialysis/peritoneal dialysis/other/missing or unknown); body mass index; comorbidities at the start of ESRD, including AIDS (yes/no/can't disclose/unknown), malignant neoplasm (yes/no/unknown), congestive heart failure (yes/no/unknown), ischemic heart disease or coronary artery disease (yes/ no/unknown) and peripheral vascular disease (yes/no/unknown). Covariate terms were included in a stepwise manner, using regression covariate selection with α = 0.1 entry and removal of significance levels. The fixed terms in the model were: age category, sex, and study cohort. These were not removed from the stepwise procedure. Patients were censored at their earliest renal transplant, completion of the follow-up period or last record in the USRDS.
Patients in the primary comparator cohort did not necessarily have a minimum of 12 consecutive weeks of phosphate-binder therapy before the screening date of individuals in the exposed cohort with whom they were matched. A sensitivity analysis was therefore performed to compare a subgroup of patients in the primary comparator cohort who had at least 12 consecutive weeks of phosphate-binder therapy.
Results

Patients
Overall, 2,026 patients were included in the LaC exposed cohort, 8,094 patients in the primary comparator cohort (those exposed to any phosphate binder other than LaC), and 8,096 patients in a historical comparator cohort (those with data available in the USRDS before the availability of LaC). Baseline demographic characteristics were similar in all 3 cohorts (Table 1) .
Primary Outcomes
After 5 years, all-cause mortality was 51.8% (1,050/2,026) and 54.4% (4,405/8,094) for patients in the exposed and primary comparator cohorts, respectively. Kaplan-Meier analysis showed that the median survival (95% CI) during the 5-year follow-up was 51.7 (49.3-54.2) and 49.0 (47.5-50.3) months for patients in the exposed and primary comparator cohorts, respectively (Fig. 1a) . There was no difference in the observed risk of all-cause mortality between the exposed and primary comparator cohorts (adjusted HR 0.94; 95% CI 0.88-1.01; p = 0.078; Table 2 ). The proportion of patients with bone-fracture events requiring hospitalization was similar in the exposed and primary comparator cohorts (6.3% [127/2,026] and 7.2% [580/8,094], respectively). The Kaplan-Meier curve of time to first bone-fracture event requiring hospitalization is shown in Figure 1b . There was no difference in the observed risk of first bone-fracture events requiring hospitalization between the exposed and primary comparator cohorts (adjusted HR 0.86; 95% CI 0.71-1.05; p = 0.130; a For the exposed cohort, baseline was the measurement taken at the screening visit. For the primary comparator cohort, baseline was the most recent measurement taken on or before the screening date, which was the screening date of the corresponding matched patient in the exposed cohort. For the historical comparator cohort, baseline was the most recent measurement taken on or before January 1, 2000;
b Age was calculated as the difference between date of birth and date of screening, truncated to years. The primary comparator cohort used the same screening date as the patient's matched individual in the exposed cohort. The screening date of the historical comparator cohort was set as January 1, 2000; c Included American Indian/Alaskan Native, Native Hawaiian/Pacific Islander and others; d Summary of region categories provided in online supplementary Table S1 ; e Exposed, n = 1,956; primary comparator, n = 7,800; historical comparator, n = 5,221; f Exposed, n = 1,954; primary comparator, n = 7,790; historical comparator, n = 5,110; g Exposed, n = 1,929; primary comparator, n = 7,672; historical comparator, n = 4,662; h Exposed, n = 2,025; primary comparator, n = 8,094; historical comparator, n = 8,096; i The length of follow-up for living patients without a transplant is from screening until the date of their last available claim record in the USRDS database; the length of follow-up for patients who received a transplant or died is from screening until their death or transplant. The maximum length of follow-up is 5 years (60 months); j 34 patients (1.7%) in the exposed cohort, 76 patients (0.9%) in the primary comparator cohort, and 138 (1.7%) patients in the historical comparator cohort received a transplant and died during the follow-up period.
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Secondary Outcomes
The incidence of specific GI disease events requiring hospitalization was 17.8% (361/2,026) and 19.1% (1549/8,094) for patients in the exposed and primary comparator cohorts, respectively. The Kaplan-Meier curve for specific GI disease requiring hospitalization is shown in Figure 2a . Use of LaC was associated with a reduced risk of specific GI disease requiring hospitalization compared with use of any other phosphate binder (primary comparator cohort; adjusted HR 0.86; 95% CI 0.76-0.97; p = 0.015; Table 2 ). The incidence of liver disease events requiring hospitalization was 5.1% a Patients who received a renal transplant between screening and 5 years (60 months), after screening, or before the event were censored at the time of the transplant; patients who did not experience the event and who did not receive a transplant within 5 years (60 months) were censored at their date of withdrawal/completion or, if not available, at their last claim date in the USRDS. b The p values were generated from separate models for each pairwise treatment comparison (exposed versus primary comparator cohorts), constructed using stepwise regression covariate selection, with α = 0.1 entry and removal of significance levels, and were not adjusted for multiplicity.
HR, hazard ratio; CPH, Cox proportional hazards; USRDS, United States Renal Data System. (104/2,026) and 6.2% (500/8,094) for patients in the exposed and primary comparator cohorts, respectively. The Kaplan-Meier curve for liver disease requiring hospitalization is shown in Figure 2b . There was no difference in the risk of liver disease requiring hospitalization between the exposed and primary comparator cohorts (adjusted HR 0.88; 95% CI 0.70-1.09; p = 0.236; Table 2 ). In addition, there was no difference in the incidence of malignancy events requiring hospitalization between the exposed and primary comparator cohorts ( Figure 2c . In terms of risk of malignancy requiring hospitalization, the CPH model indicated no difference between the exposed and primary comparator cohorts (adjusted HR 0.85; 95% CI 0.54-1.34; p = 0.496; Table 2 ). The incidence of major infectious episodes requiring hospitalization was lower in patients exposed to LaC (46.2% [936/2,026]) than in those in the primary comparator cohort (49.3% [3991/8,094]). The median times to first major infectious episode (95% CI) during the 5 years of follow-up were 54.8 (49.9-59.6) and 47.0 (45.0-49.2) months for patients in the exposed and primary comparator cohorts, respectively (Fig. 2d) . Use of LaC was associated with a reduced risk of major infectious episodes requiring hospitalization compared with use of any other phosphate binder (primary comparator cohort) (adjusted HR 0.87; 95% CI 0.80-0.94; p < 0.001; Table 2 ).
Additional Analyses Historical Comparator Cohort
In the historical comparator cohort, the incidence of all-cause mortality was 62.7% (5,073/8,096) and, during the 5 years of follow-up, median survival (95% CI) was 38.2 (37.2-39.6) months (Fig. 1a) . Patients who had been exposed to LaC had a reduced risk of all-cause mortality compared with the historical comparator cohort (adjusted HR 0.75; 95% CI 0.70-0.81; p < 0.001; Table 3 ). The incidence of bone fractures requiring hospitalization was 6.9% (556/8,096) for the historical comparator cohort. The Kaplan-Meier survival curve for time to first bone-fracture event requiring hospitalization for the historical comparator cohort is shown in Figure 1b . There was no difference in the risk of first bone-fracture event requiring hospitalization for patients in the exposed cohort and those in the historical comparator cohort (adjusted HR 0.83; 95% CI 0.68-1.01; p = 0.062; Table 3 ).
The incidences of secondary outcomes in the historical comparator cohort were: specific GI disease requiring hospitalization, 20.5% (1,663/8,096); liver disease requiring hospitalization, 4.3% (352/8,096); malignancy requiring hospitalization, 1.3% (108/8,096); and major infectious episode requiring hospitalization, 44.2% (3,575/8,096). With the exception of the incidence of specific GI disease requiring hospitalization, which was lower in the exposed cohort than in the historical comparator cohort, incidences of all other secondary outcome measures were similar in the 2 cohorts. LaC (exposed cohort) was associated with a reduced risk of specific GI disease (adjusted HR 0.75; 95% CI 0.66-0.85; p < 0.001) and major infectious episodes requiring hospitalization (adjusted HR 0.89; 95% CI 0.81-0.96; p = 0.004) versus the historical comparator cohort (Table 3 ). There was no difference between these 2 cohorts for risk of liver disease or malignancy requiring hospitalization (Table 3) .
Sensitivity Analysis Of the 8,094 patients in the primary comparator cohort, 2,422 had received a minimum of 12 consecutive weeks of phosphate-binder therapy before screening. A Kaplan-Meier analysis of this subgroup of patients revealed that the median survival (95% CI) with 5 years of follow-up was 44.5 (41.4-46.7) months (online suppl. Fig.  S1 ). For the CPH model, treatment with LaC was associated with a reduced risk of all-cause mortality and reduced risk of first bone-fracture event compared with primary comparator patients in this subgroup (all-cause mortality: adjusted HR 0.88; 95% CI 0.81-0.96; p = 0.003; first bone fracture: adjusted HR 0.78; 95% CI 0.62-0.98; p = 0.030). a Patients who received a renal transplant between screening and 5 years (60 months), after screening, or before the event were censored at the time of the transplant; patients who did not experience the event and who did not receive a transplant within 5 years (60 months) were censored at their date of withdrawal/completion or, if not available, at their last claim date in the USRDS. b The p values were generated from separate models for each pairwise treatment comparison (exposed versus historical comparator cohorts), constructed using stepwise regression covariate selection, with α = 0.1 entry and removal of significance levels, and were not adjusted for multiplicity.
HR, hazard ratio; CPH, Cox proportional hazards; USRDS, United States Renal Data System.
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Discussion
This study used 5-year follow-up data from the USRDS to examine the long-term safety of LaC in patients with ESRD. The analysis found that LaC was not associated with an increased risk of all-cause mortality or first bonefracture events requiring hospitalization compared with patients taking other phosphate binders during the same time period. The conclusions of this study did not change in a sensitivity analysis conducted to account for potential immortal time bias due to differences between the exposed and primary comparator cohorts [26] . The finding of lower all-cause mortality compared with the historical comparator cohort might be expected, given the changes in patients' standard of care since 2000. The secondary outcomes further supported the positive safety profile of LaC, demonstrating that LaC was not associated with an increased risk of specific GI disease, liver disease, malignancy, or infectious episodes requiring hospitalization compared with either of the comparator cohorts.
These findings are concordant with those of a recent 10-year safety review of the literature [18] , which showed LaC to be minimally absorbed and eliminated primarily by hepatobiliary excretion [27] . Randomized prospective studies of paired bone biopsies also showed that LaC was not associated with bone toxicity or mineralization defects [10, 28] , and no clinically relevant changes in liver enzymes or bilirubin were noted [29] . In addition, LaC does not cross the blood-brain barrier, unlike aluminum-based binders [5, 22] , and adverse events reported by patients receiving LaC are comparable to those reported by patients taking other non-aluminum-based binders (including calcium carbonate, sevelamer hydrochloride, or standard therapy), with the exception of hypercalcemia events, which are higher in patients receiving calcium-based binders [3, 15, 30] .
The strengths of this study were the large population of patients included in the analysis; it comprised a total of 18 216 patients with ESRD (exposed, n = 2,026; primary comparator, n = 8,094; historical comparator, n = 8,096), and the inclusion of long-term follow-up data from the USRDS -a large database of patients with ESRD in the USA [25, 31] .
A limitation of this study was that patients receiving Medicare may not be representative of patients with other forms of insurance coverage or the general population. As a result, interpretation of hospitalization data may not be generalizable to those not in the Medicare population and should be interpreted with care. We further acknowledge the limitation with the different approaches used to identify the exposed cohort and the primary comparator cohort. Patients in the primary comparator cohort were identified from the USRDS and, as such, did not have eligibility requirements. With the observation period spanning 5 years, it was not possible to obtain the target primary comparator cohort (patients not exposed to LaC during the follow-up period) with a prospective selection method. Nevertheless, baseline and demographic characteristics that were collected in USRDS were similar in the 2 cohorts. In addition, a sensitivity analysis of time to all-cause mortality was performed, in which both exposed and primary comparator cohorts were included if they had a minimum of 12 consecutive weeks of phosphate binder use (any phosphate binder other than LaC for the primary comparator cohort). The ICD-9 codes used in the analysis did not capture some stomach, duodenum or functional digestive disorders, therefore the incidence of GI disorders could potentially be slightly underestimated (for all cohorts). Another possible source of bias was the potential for residual confounding, which can be a limitation of observational studies [32] . Furthermore, data on dose or duration of phosphate binder therapy were not collected for the study comparator cohorts. Data on use of LaC in the exposed cohort (as part of normal clinical practice) were collected up to study site closure. After study site closure, data on use of LaC were not collected and defaulted to "no exposure" (thus with a likely underestimation of LaC actual use, especially at later time points). Based on this, 73.2% (1,483/2,026) of patients in the exposed cohort were known to be on LaC at month 6; 57.5% (1,165/2,026) at month 12; and 1.3% (26/2,026) at month 60.
The primary comparator cohort was used as the main comparator for this analysis because patients in this group formed a more appropriately matched cohort than those in the historical comparator cohort. First, patients in the exposed and primary comparator cohorts were treated for hyperphosphatemia at approximately the same time (matched by first calendar year of starting dialysis [±1 year]); and secondly, the 2 cohorts had similar comorbidity profiles at baseline. Patients in the historical comparator cohort were instead exposed to a different standard of care at the time of data input. Changes in data-collection methods and quality of data may have also affected this cohort. There are also limitations associated with using data from the USRDS, including a lack of continuous validation of its data acquisition, a lack of complete comorbidity and laboratory data, constraints in matching the comparator groups from the registry database, potential survival and attrition biases, unmeasured variables, and a lack of accuracy in reporting cause of death [31] . To overcome the limitation of missing data, patients in the ex- posed group were identified in the USRDS by matching combinations of non-missing data from the case-report form with non-missing data from the USRDS.
In conclusion, this post-marketing observational study is the first to present long-term follow-up data from the USRDS for patients with ESRD in the USA receiving LaC. This analysis shows that patients receiving LaC are not at an increased risk of all-cause mortality, first bone-fracture events requiring hospitalization, or any of the secondary safety outcomes assessed, compared with patients receiving therapy with any other phosphate binder.
